Skip to main content
. 2021 Oct 22;6(20):e151477. doi: 10.1172/jci.insight.151477

Figure 4. SARS-CoV-2 antibody profile of RecoVax and NaiveVax cohorts from baseline to about 6 months postvaccination.

Figure 4

TAb antibody response (A), SNAb levels (B), avidity (C), and anti-S (D) of RecoVax individuals (red circle; total n = 66) and NaiveVax individuals (blue triangle; total n = 201) after the first (D1) and second (D2) doses of the vaccine. Comparisons were made at baseline (median 1 day; IQR 0–6 days after D1), prior to D2 (median 16 days after D1; IQR 15–21), approximately 2 weeks after D2 (median 35 days after D1; IQR 34–36), approximately 4 weeks after D2 (median 49 days after D1; IQR 49–52), approximately 3 months after D1 (median 100 days after D1; IQR 97–105), and approximately 6 months after D1 (median 168 days after D1; IQR 164–170). Horizontal black lines represent median values and whiskers represent 95% CI. Wilcoxon’s rank-sum was used for paired comparison while Kruskal-Wallis test was used for the comparison of 3 or more groups. S, spike.